Obstructive Sleep Apnea as a Risk Factor for Normal Tension Glaucoma and a Crucial Step in Preventing Blindness

Part of paid clinical trials in New York, New York.

Sponsor
Northwell Health
Study ID
NCT06023927
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Normal Tension Glaucoma
  • Obstructive Sleep Apnea

Eligibility Criteria

Sex
ALL
Age
21 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Clinical observation, diagnostic testing — OTHER
    Glaucoma evaluation including structural and functional diagnostic testing at baseline and 3 subsequent follow-up visits over a period of 9 months

Study Details

The purpose of this research study is to learn more about the relationship between Obstructive Sleep Apnea (OSA) and Normal Tension Glaucoma (NTG). OSA is a nighttime disorder of the upper airway that causes an intermittent lack of oxygen while sleeping. NTG is a type of glaucoma that occurs despite the normal intraocular pressure levels, making its detection more difficult. Left untreated, irreversible optic nerve damage and extensive vision loss can result. Previous research has shown some evidence between OSA and the development of NTG. The investigators are researching whether undergoing treatment for OSA would help to improve the vascular health to the retina, and in effect, improve the early signs of visual dysfunction seen with diagnostic testing.

Key Dates

Start date
Sep 2, 2025
Status verified
Jun 2025
Primary completion
Sep 1, 2027
Completion
Sep 1, 2028

Study Design

Enrollment
100 participants (estimated)

Arms

  • Arm: Newly-diagnosed mild OSA - initiating CPAP treatment
    Subjects with newly-diagnosed mild obstructive sleep apnea being treated with CPAP undergoing clinical observation/diagnostic evaluation for detection and tracking of NTG.
  • Arm: Newly-diagnosed moderate OSA - initiating CPAP treatment
    Subjects with newly-diagnosed moderate obstructive sleep apnea being treated with CPAP undergoing clinical observation/diagnostic evaluation for detection and tracking of NTG.
  • Arm: Newly-diagnosed severe OSA - initiating CPAP treatment
    Subjects with newly-diagnosed severe obstructive sleep apnea being treated with CPAP undergoing clinical observation/diagnostic evaluation for detection and tracking of NTG.

Primary Outcome Measure

Prevalence of NTG [ Time Frame: 2 years ]

Locations (2)

FacilityCityStateZIPSite coordinators
Manhattan Eye, Ear, & Throat HospitalNew YorkNew York10065
Andrew Tirsi, MD
[email protected]
201-982-4168
Celso Tello, MD (PRINCIPAL_INVESTIGATOR)
Stephen Obstbaum, MD (SUB_INVESTIGATOR)
Sung Chul Park, MD (SUB_INVESTIGATOR)
Yosef Krespi, MD (SUB_INVESTIGATOR)
Tirsi Andrew, MD (SUB_INVESTIGATOR)
Manhattan Eye, Ear, & Throat HospitalNew YorkNew York10065
Andrew Tirsi, MD
[email protected]
201-982-4168
Tirsi
[email protected]
Celso Tello, MD (PRINCIPAL_INVESTIGATOR)
Stephen Obstbaum, MD (SUB_INVESTIGATOR)
Sung Chul Park, MD (SUB_INVESTIGATOR)
Yosef Krespi, MD (SUB_INVESTIGATOR)
Tirsi Andrew, MD (SUB_INVESTIGATOR)

Find similar trials in New York, NY

By research site
Manhattan Eye, Ear, & Throat Hospital· New York, NY

Related Studies